3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Urinary Tract Infections
1
Urinary Bladder Neoplasms
1
Surgical Wound Infection
1
Skin Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Infections
1
Head and Neck Neoplasms
1
Exanthema
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gels
2
Fulvestrant
2
Doxycycline
2
Dapsone
2
ruxolitinib
1
dexpanthenol
1
ceterizine hydrochloride
1
capivasertib
1
benralizumab
1
Triamcinolone Acetonide
1
Tetracycline
1
Sirolimus
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Loperamide
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Erlotinib Hydrochloride
1
Clindamycin
1
Cetuximab
1
Anti-Bacterial Agents
1
Alpelisib
1
Acitretin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Exanthema
×
Clindamycin
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts